Genome & Company

₩3,145As of Sun 8 Nov 2026, 12:00 UTC
KOSDAQ:314130Healthcare
Country South Korea
PE (Fwd) •••
TSR 8Y CAGR (8.18%)
Div yield —
ROE (47.10%)
Biological Products, Except Diagnostic Substances
Beta (5Y) 0.39
PE TTM —
TSR TTM (1.72%)
Mkt cap ₩164.5B
ROIC (15.49%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
₩3,175
0.96%
107.14%
Hold 1|4|10|2|9
4Q25
1Q26
2Q26
3Q26
Earnings per share₩
32.40
30.78
32.55
33.47
11.73%
4.44%
2.31%
8.81%
Revenue₩B
18.44
18.36
18.82
19.70
3.19%
4.21%
4.91%
8.34%
Peers (US$121.3M)
Cap (US$)
PE
124.0M
—
122.7M
—
Capital
TTM
5Y
10Y
Leveragex
0.380
(0.131)
(0.125)
EBIT/Intx
0.672
0.071
0.067
Own earn%
26.48
95.43
86.16
Sh yield%
36.30
24.13
24.45
Owners
Insiders/Inst%
5.73
43.20
Short interest%
3.84
SBC / revenue%
0.58
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
14
Op margin range%
32–44
$1 testx
−0.5
Incr. ROIC%
5